Department of Biological Chemistry, Medical School, National and Kapodistrian University of Athens, 75 Mikras Asias, Goudi, 11527 Athens, Greece.
Laboratory of Clinical Biochemistry & Laboratory of Hematology and Blood Bank Unit, Medical School, National and Kapodistrian University of Athens, Attikon General University Hospital, 1 Rimini Street, Chaidari, 12462 Athens, Greece.
Biomolecules. 2021 Oct 30;11(11):1609. doi: 10.3390/biom11111609.
Aberrant circulating omentin-1, which is an anti-inflammatory and pro-apoptotic adipokine, has been reported in various solid tumors. Therefore, we investigated whether or not circulating omentin-1 could be associated with postmenopausal BC (PBC) and could be used as a potential diagnostic and clinical tool taking into consideration clinicopathologic features, tumor markers, as well as anthropometric, metabolic, and inflammatory parameters. Serum omentin-1, tumor markers (CA15-3 and CEA); metabolic (insulin, glucose, HOMA index, and serum lipids), anthropometric (BMI, waist circumference, and fat mass), and inflammatory (TNF-α, IL-6, hsCRP) parameters; classic adipokines (leptin and adiponectin); the Mediterranean diet (MedDiet) score; and cardiovascular (CVD) risk were determined in 103 postmenopausal women with pathologically confirmed incident invasive BC, 103 controls matched on age, 51 patients with benign breast lesions (BBL), and 50 obese postmenopausal women of similar age. The mean serum omentin-1 was significantly lower in cases than in controls and patients with BBL ( < 0.001). In the patients, omentin-1 was inversely associated with tumor, metabolic and inflammatory biomarkers, cancer stage, and the number of infiltrated lymph nodes ( < 0.05). In all study participants, omentin-1 was negatively correlated with CVD risk and positively correlated with MedDiet score. Lower circulating omentin-1 was independently associated with PBC occurrence above and beyond known risk factors. According to the ROC curve analysis, the overall diagnostic performance of omentin-1 (0.84, 95% CI 0.79-0.89) is similar to CA15-3. Circulating omentin-1 may be a biomarker at the intersection of PBC and cardiometabolic risk in postmenopausal women, and could be modulated by the adoption of a MedDiet. Further mechanistic and large multicentric prospective and longitudinal studies are required to elucidate the ontological role of omentin-1 in BC and CVD risks, as well as its diagnostic and prognostic ability and its therapeutic potential.
异常循环的网膜素-1 是一种具有抗炎和促凋亡作用的脂肪因子，已在各种实体瘤中报道。因此，我们研究了循环网膜素-1 是否与绝经后乳腺癌 (PBC) 相关，并且是否可以作为一种潜在的诊断和临床工具，考虑到临床病理特征、肿瘤标志物以及人体测量学、代谢和炎症参数。我们测定了 103 例经病理证实的浸润性乳腺癌绝经后女性、103 例年龄匹配的对照组、51 例良性乳腺病变 (BBL) 患者和 50 例年龄相似的肥胖绝经后女性的血清网膜素-1、肿瘤标志物 (CA15-3 和 CEA)、代谢 (胰岛素、葡萄糖、HOMA 指数和血清脂质)、人体测量学 (BMI、腰围和脂肪量) 和炎症 (TNF-α、IL-6、hsCRP) 标志物、经典脂肪因子 (瘦素和脂联素)、地中海饮食 (MedDiet) 评分和心血管 (CVD) 风险。与对照组和 BBL 患者相比，病例组的血清网膜素-1水平显著降低（<0.001）。在患者中，网膜素-1与肿瘤、代谢和炎症生物标志物、癌症分期和浸润性淋巴结数量呈负相关（<0.05）。在所有研究参与者中，网膜素-1与 CVD 风险呈负相关，与 MedDiet 评分呈正相关。循环网膜素-1降低与 PBC 的发生独立相关，超出了已知的危险因素。根据 ROC 曲线分析，网膜素-1的整体诊断性能（0.84，95%CI 0.79-0.89）与 CA15-3 相似。循环网膜素-1可能是绝经后妇女 PBC 和代谢心血管风险的交汇点生物标志物，并且可以通过采用 MedDiet 来调节。需要进一步的机制和大型多中心前瞻性和纵向研究来阐明网膜素-1在乳腺癌和 CVD 风险中的本体作用，以及其诊断和预后能力及其治疗潜力。
